ANTIBODIES TO ICOS

• Main Authors: SATHYANARAYANAN SRIRAM, SAZINSKY STEPHEN, MICHAELSON JENNIFER S, ELPEK KUTLU GOKSU
• Format: Patent
• Language: Chinese; English
• Published: 02.01.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPIRITS; VINEGAR; WINE

Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.In some embodiments, an isolated antibody that blinds ICOS is provided, wherein the antibody is an agonist of CD4 T cells (such as CD4 T effector (Teff) cells). In some embodiments, an isolated antibody that binds ICOS is provided, wherein the antibody is an agonist of CD4 T cells (such as CD4 Teff cells) and depletes T regulatory (Treg) cells. In some embodiments, an isolated antibody that bindsICOS is provided, wherein the antibody depletes Treg cells, but does not deplete Teff cells. 本文提供关于抗体的各种实施方案。所述实施方案中的些包括结合ICOS的激动剂抗体。此类抗体可用于治疗例如癌症的方法中。在些实施方案中，提供结合ICOS的分离的抗体，其中所述抗体为CD4 T细胞(诸如，CD4 T效应(Teff)细胞)的激动剂。在些实施方案中，提供结合ICOS的分离的抗体，其中所述抗体为CD4 T细胞(诸如CD4 Teff细胞)的激动剂，并且耗尽T调控(Treg)细胞。在些实施方案中，提供结合ICOS的分离的抗体，其中所述抗体耗尽Treg细胞，但不耗尽Teff细胞。